BioPlatinum Technologies is a therapeutics and biomarker company advancing new opportunities in platinum-based medicine.

Platinum-based therapies remain among the most important treatment tools in oncology, yet patients receiving similar therapies can experience very different outcomes. BioPlatinum was founded to investigate why.

Our work connects disease biology, biomarker research, and therapeutic development to better understand treatment response, therapeutic activity, and resistance. BioPlatinum’s lead therapeutic program, Triplatin, builds on years of research in platinum therapeutics, while our biomarker research includes work on chondroitin-4-sulfate (C4S), a potential biomarker associated with platinum response in ovarian cancer.

By deepening the understanding of how platinum-based medicines interact with disease biology, BioPlatinum is working to inform future therapeutics, biomarkers, and treatment strategies.

We welcome conversations with investors, strategic partners, researchers, and industry collaborators interested in advancing therapeutic and biomarker innovation in platinum-based medicine.


Bioplatinum Technologies

Org chart

Teams

Offices

Bioplatinum Technologies

Org chart

Teams

Offices

Related companies